P1102: A PHASE 1 STUDY OF PARSACLISIB IN COMBINATION WITH RITUXIMAB, BENDAMUSTINE + RITUXIMAB, OR IBRUTINIB IN PATIENTS WITH PREVIOUSLY TREATED B-CELL LYMPHOMA (CITADEL-112): PRELIMINARY SAFETY RESULTS. (23rd June 2022) - Sancho, J.-M.; Lopez-Guillermo, A.; Abrisqueta, P.; Kumar, A.; Cordoba, R.; Tani, M.; Zhao, W.; Rappold, E.; Langmuir, P.; Mims, M.